AU2024263657A1 - Combined use of bispecific antibody binding to activated coagulation factor ix and coagulation factor x with blood coagulation factor x for treating subject with hemophilia a - Google Patents

Combined use of bispecific antibody binding to activated coagulation factor ix and coagulation factor x with blood coagulation factor x for treating subject with hemophilia a

Info

Publication number
AU2024263657A1
AU2024263657A1 AU2024263657A AU2024263657A AU2024263657A1 AU 2024263657 A1 AU2024263657 A1 AU 2024263657A1 AU 2024263657 A AU2024263657 A AU 2024263657A AU 2024263657 A AU2024263657 A AU 2024263657A AU 2024263657 A1 AU2024263657 A1 AU 2024263657A1
Authority
AU
Australia
Prior art keywords
factor
coagulation factor
blood coagulation
hemophilia
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024263657A
Other languages
English (en)
Inventor
Yuto NAKAJIMA
Hirotoshi Nakano
Keiji Nogami
Kazuki Shimizu
Eisuke TAKAMI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nara Medical University PUC
KM Biologics Co Ltd
Original Assignee
Nara Medical University PUC
KM Biologics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nara Medical University PUC, KM Biologics Co Ltd filed Critical Nara Medical University PUC
Publication of AU2024263657A1 publication Critical patent/AU2024263657A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2024263657A 2023-04-28 2024-04-26 Combined use of bispecific antibody binding to activated coagulation factor ix and coagulation factor x with blood coagulation factor x for treating subject with hemophilia a Pending AU2024263657A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023-074020 2023-04-28
JP2023074020 2023-04-28
PCT/JP2024/016461 WO2024225440A1 (ja) 2023-04-28 2024-04-26 血友病ａを有する対象の処置のための、活性化凝固第ｉｘ因子及び凝固第ｘ因子と結合する二重特異性抗体と血液凝固第ｘ因子の併用

Publications (1)

Publication Number Publication Date
AU2024263657A1 true AU2024263657A1 (en) 2025-11-13

Family

ID=93256843

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024263657A Pending AU2024263657A1 (en) 2023-04-28 2024-04-26 Combined use of bispecific antibody binding to activated coagulation factor ix and coagulation factor x with blood coagulation factor x for treating subject with hemophilia a

Country Status (6)

Country Link
EP (1) EP4702987A1 (https=)
JP (1) JPWO2024225440A1 (https=)
KR (1) KR20250174932A (https=)
CN (1) CN121013727A (https=)
AU (1) AU2024263657A1 (https=)
WO (1) WO2024225440A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
JP6698102B2 (ja) * 2015-04-17 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝固因子と多重特異的抗体を用いた併用療法

Also Published As

Publication number Publication date
JPWO2024225440A1 (https=) 2024-10-31
KR20250174932A (ko) 2025-12-15
WO2024225440A1 (ja) 2024-10-31
CN121013727A (zh) 2025-11-25
EP4702987A1 (en) 2026-03-04

Similar Documents

Publication Publication Date Title
US9090697B2 (en) Methods for treating bleeding disorders
Ziliotto et al. Coagulation pathways in neurological diseases: multiple sclerosis
KR102057767B1 (ko) 응고 인자 및 다중특이적 항체의 조합 요법
AU2009279804C1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
JP6705785B2 (ja) トロンビン結合性抗体分子及びその使用
JP2003527861A (ja) 増強した抗血液凝固能を持つ抗組織因子抗体
JP2019505527A (ja) 抗凝固因子ｘｉ抗体
KR20190052027A (ko) 응고 인자 결합 단백질 및 이의 용도
EP1647596A2 (en) Monoclonal antibody against platelet membrane glycoprotein vi
US10144784B2 (en) Monoclonal antibodies against antithrombin beta
KR20180096567A (ko) Xiia 인자의 단일클론 항체 저해제
Gandhi et al. A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders
JP7319721B2 (ja) 抗凝固因子ＸＩ活性型因子ＸＩａ抗体並びにその調製方法及び使用
Anandani et al. The implication of new developments in hemophilia treatment on its laboratory evaluation
US20190194354A1 (en) Tissue Plasminogen Activator Antibodies and Methods of Use
CA2934081A1 (en) Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof
JP7535849B2 (ja) 出血治療のための止血促進タンパク質
AU2024263657A1 (en) Combined use of bispecific antibody binding to activated coagulation factor ix and coagulation factor x with blood coagulation factor x for treating subject with hemophilia a
Bou-Jaoudeh et al. Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab
WO2023245335A1 (en) Activators of coagulation factor x and formulations thereof for treating bleeding disorders
WO2004041302A1 (en) Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator
US20040198660A1 (en) Tissue factor antagonist and protein C polypeptide compositions
AU2016231328A1 (en) Compounds for improving the half-life of von Willebrand factor
SHIMA Studies on factor VIII toward a new therapeutic for hemophilia A
WO2025192741A1 (ja) 活性化血液凝固第ｖｉｉ因子及び血液凝固第ｘ因子を含む医薬組成物